The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    SKB-315
Previous Study | Return to List | Next Study

A Study of SKB315 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05367635
Recruitment Status : Recruiting
First Posted : May 10, 2022
Last Update Posted : October 24, 2023
Sponsor:
Information provided by (Responsible Party):
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: SKB315 for injection Phase 1

Detailed Description:
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, PK profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.The study is divided into Phase 1a and Phase 1b: Phase 1a is a dose escalation study to determine the maximum tolerated dose(MTD); Phase 1b is a dose expansion study to conduct preliminary evaluation of anti-tumor efficacy and further evaluation of safety, tolerability, PK, and immunogenicity of SKB315.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 206 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2
Actual Study Start Date : March 16, 2022
Estimated Primary Completion Date : May 31, 2024
Estimated Study Completion Date : May 31, 2024
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Phase 1a：Dose escalation
Eleven dose levels are tentatively planned for Phase 1a
 Drug: SKB315 for injection
SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
Experimental: Phase 1b: Dose expansion
The dose of SKB315 for injection in Phase 1b is selected based on the Phase 1a monotherapy dose escalation study.
 Drug: SKB315 for injection
SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Phase 1a: Dose Limiting Toxicities (DLT) [ Time Frame: From data of initial dose until up to 21/28 days for treatment ]
    Incidence of Dose Limiting Toxicities

  2. Phase 1b: Objective Response Rate (ORR) [ Time Frame: Up to 2 years ]
    The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases.


Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Up to 2 years ]
    PFS: Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.

  2. Duration of Response (DOR) [ Time Frame: Up to 2 years ]
    DOR: Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.

  3. Overall Survival (OS) [ Time Frame: Up to 2 years ]
    OS: Time from start of treatment to death due to any reason.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients aged 18 to 80 years (inclusive) at the time of signing the informed consent form (ICF);
  2. Patients with histologically and/or cytologically confirmed advanced solid tumors who have failed standard of care, or who have no available standard of care regimen, or who are unqualified for standard of care;
  3. Consent to provide archival or fresh tumor tissue slides for immunohistochemistry (IHC) assessment, and advanced solid tumors with Claudin 18.2 expression as determined by IHC;
  4. Presence of at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
  5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
  6. Estimated survival ≥ 3 months as judged by the investigator;
  7. Adequate organ and bone marrow function (no blood components and cytokines are allowed within 2 weeks prior to the first dose) ;
  8. Have recovered to ≤ Grade 1 (according to national cancer institute (NCI) common terminology criteria adverse events (CTCAE) V5.0) from previously treated toxicity prior to the first dose of study treatment;
  9. Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 6 months after the end of dosing;
  10. Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.

Exclusion Criteria:

  1. Received other drugs in clinical study, major surgeries, or any other anti-tumor therapies within 4 weeks prior to the first dose of study treatment;
  2. Received any previous therapy targeting Claudin18.2;
  3. Plan to receive any other anti-tumor therapy during the study;
  4. Received strong cytochrome P450 3A4(CYP3A4) inhibitors or inducers within 2 weeks prior to the first dose of study treatment or within 5 half-lives of drug elimination, whichever is longer;
  5. Have other malignancies within 5 years prior to signing of ICF;
  6. Pregnant or lactating women;
  7. Known history of allergy to any component of SKB315 or other monoclonal antibodies (mAbs);
  8. Known history of alcohol abuse (consumption of more than 14 units of alcohol per week or drug abuse);
  9. Patients with active hepatitis B or hepatitis C;
  10. Human immunodeficiency virus (HIV) positive;
  11. Active severe digestive disease;
  12. History of major cardiovascular diseases
  13. Confirmed serious lung disease or lung disease that may impair the respiratory reserve function of the patient as judged by the investigator;
  14. History of serious dementia, altered mental status, or any psychiatric disorder;
  15. Concomitant or known metastases to brain or central nervous system;
  16. Have clinically significant systemic diseases that may adversely affect the safety of the study;
  17. Subjects who may have poor compliance with the clinical study or have other factors based on which the investigator considers that the subjects are not appropriate to participate in the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05367635


Contacts
Layout table for location contacts
Contact: Yi Ba, Professor 022-23340123 bayi@tjmuch.com

Locations
Layout table for location information
China, Tianjin
Tianjin Medical University Cancer Institute & Hospital Recruiting
Tianjin, Tianjin, China, 300060
Contact: Yi Ba, Professor       bayi@tjmuch.com   
Sponsors and Collaborators
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yi Ba, Professor Tianjin Medical University Cancer Institute & Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
ClinicalTrials.gov Identifier: NCT05367635    
Other Study ID Numbers: SKB315-I-01
First Posted: May 10, 2022    Key Record Dates
Last Update Posted: October 24, 2023
Last Verified: October 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms